With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise.
The biotechnology sector, as represented by the XBI ETF, is trading lower due to a market-wide rotation out of high-growth, speculative areas and into more defensive assets. This trend has been particularly pronounced as investors shift away from technology and AI-related stocks, which have recently faced selling pressure. The move is impacting small-cap biotech firms, which are more sensitive to changes in investor risk appetite, while large-cap pharmaceutical companies have seen increased interest.